- Thinly traded nano cap Neuralstem (CUR +67%) jumps on a whopping 55x surge in volume in response to new data on lead candidate NSI-189 in major depressive disorder (MDD). The results were presented at the American College of Neuropsychopharmacology Annual Meeting in Palm Springs, CA.
- Patients receiving the 40 mg dose experienced statistically significant improvements in MDD symptoms as measured by scales called SDQ and CPFQ. There was also a statistically greater reduction in scores of another metric called QIDS-SR versus placebo in Stage 2 of the study.
- The 80 mg dose failed to beat placebo.
- The company intends to meet with the FDA in H1 2018 to discuss the results and a regulatory path to approval. It also plans to submit the data for publication.
- The company says small molecule NSI-189, a benzylpiperazine-aminopyridine, stimulates neurogenesis, synaptogenesis and increases hippocampal volume, all of which play a role in reversing depression, enhancing cognition and promoting the growth of new nerve tissue.
- Previously: Neuralstem's NSI-189 flunks mid-stage study in MDD; shares plummet 61% premarket (July 25)
- Now read: Cidara Therapeutics: An Attractive Price For A Niche Opportunity With A High Probability Of Success
Original article